{"id":"compound-edaravone-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL290916","moleculeType":"Small molecule","molecularWeight":"174.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edaravone works by directly scavenging free radicals, particularly hydroxyl radicals generated during ischemic and reperfusion injury. By reducing oxidative stress in neural tissue, it limits secondary neuronal damage and apoptosis following acute ischemic stroke. This mechanism helps preserve neurological function and improve recovery outcomes in the acute phase of stroke.","oneSentence":"Edaravone is a free radical scavenger that reduces oxidative stress and neuronal damage by neutralizing hydroxyl radicals and other reactive oxygen species.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:23.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT04219865","phase":"PHASE1","title":"Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-06-05","conditions":"Pharmacokinetics","enrollment":40},{"nctId":"NCT04218513","phase":"PHASE1","title":"Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-05-10","conditions":"Drug-drug Interaction","enrollment":24},{"nctId":"NCT02430350","phase":"PHASE3","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT01929096","phase":"PHASE2","title":"Compound Edaravone Injection for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Acute Ischemic Stroke","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Compound Edaravone Injection","genericName":"Compound Edaravone Injection","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edaravone is a free radical scavenger that reduces oxidative stress and neuronal damage by neutralizing hydroxyl radicals and other reactive oxygen species. Used for Acute ischemic stroke, Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}